.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Queensland Health
Mallinckrodt
Julphar
Novartis
McKinsey
Boehringer Ingelheim
QuintilesIMS
Fish and Richardson

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Sign Up

« Back to Dashboard

Details for Patent: ➤ Sign Up

Title:Salt of naphthyridine carboxylic acid derivative
Abstract: A composition comprising 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-- oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate hydrate and their use in antibacterial therapy.
Inventor(s): Kim; Ae Ri (Daejeon, KR), Lee; Jin Hwa (Daejeon, KR), Park; Ki Sook (Daejeon, KR), Choi; Jong Ryoo (Daejeon, KR), Lee; Tae Hee (Daejeon, KR), Chang; Jay Hyok (Daejeon, KR), Nam; Do Hyun (Daejeon, KR), Choi; Hoon (Daejeon, KR)
Assignee: LG Life Sciences, Ltd. (KR)
Filing Date:Dec 07, 2006
Application Number:11/635,069
Claims:1. A method of treating a respiratory tract infection in a human or animal, comprising administering a therapeutically effective amount of a composition comprising 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-- oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate hydrate and a pharmaceutically acceptable carrier or excipient to a human or animal with a respiratory tract infection.

2. A method of treating a urinary tract infection in a human or animal, comprising administering a therapeutically effective amount of a composition comprising 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-- oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate hydrate and a pharmaceutically acceptable carrier or excipient to a human or animal with a urinary tract infection.

3. The method of claim 1, wherein the hydration number of the methanesulfonate hydrate is 1.5.

4. The method of claim 1, wherein the hydration number of the methanesulfonate hydrate is 3.0.

5. The method of claim 2, wherein the hydration number of the methanesulfonate hydrate is 1.5.

6. The method of claim 2, wherein the hydration number of the methanesulfonate hydrate is 3.0.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
US Department of Justice
Federal Trade Commission
Fuji
US Army
Cerilliant
UBS
QuintilesIMS
Fish and Richardson
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot